The global AI in clinical trials market, valued at US$1.20 billion in 2023, is projected to grow at a 12.4% annually, reaching US$2.74 billion by 2030. As AI reshapes how patients are identified, matched, and enrolled in clinical research, regulatory frameworks must evolve to address the structural diversity, data flows, and ethical risks embedded in these emerging platforms.